Pharmaceuticals France

France KRAS Inhibitors Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France KRAS Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $23.9 Mn Placeholder estimate
Estimate 2025 $32.1 Mn 2.9% of the global market
Projected 2034 $456.3 Mn 1,321.3% Adds $424.2 Mn over 9 forecast years
CAGR 2025–2034 34.3% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • France is 2.94% of the global market.
  • In Europe, the largest is Germany at $36.5 Mn.
  • Fastest growing: Italy at 34.9% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$424.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
KRAS Inhibitors Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $23.9 Mn — —
2025 (base) $32.1 Mn +$8.2 Mn —
2026 (forecast) $43.1 Mn +$11.0 Mn +34.3%
2027 (forecast) $57.9 Mn +$14.8 Mn +80.4%
2028 (forecast) $77.8 Mn +$19.9 Mn +142.2%
2029 (forecast) $104.4 Mn +$26.7 Mn +225.3%
2030 (forecast) $140.3 Mn +$35.8 Mn +336.9%
2031 (forecast) $188.4 Mn +$48.1 Mn +486.8%
2032 (forecast) $253.0 Mn +$64.6 Mn +688%
2033 (forecast) $339.8 Mn +$86.8 Mn +958.3%
2034 (forecast) $456.3 Mn +$116.5 Mn +1,321.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France KRAS Inhibitors Market Analysis at a glance
Market size, 2025$32.1 Mn placeholder estimate
Forecast, 2034$456.3 Mn placeholder estimate
Growth (CAGR), 2025–203434.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersAmgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines, Novartis AG (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
Active clinical trials58 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France KRAS Inhibitors Market Analysis Executive Summary

KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.

Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).

Bar chart: France KRAS Inhibitors market size, 2024–2034, placeholder estimates. $23.9 Mn in 2024, $32.1 Mn in 2025 and $456.3 Mn in 2034, 34.3% CAGR.
France KRAS Inhibitors market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France KRAS Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for KRAS Inhibitors Market in France

The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for KRAS Inhibitors Market in France

KRAS Inhibitors in France: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] ClinicalTrials.gov lists 58 studies on KRAS Inhibitors that are recruiting, active or about to start in France.⁠[3]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in KRAS Inhibitors right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

KRAS Inhibitors in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the KRAS Inhibitors market in France?
Placeholder estimate: about $32.1 Mn in 2025, rising to about $456.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the KRAS Inhibitors market in France growing?
Placeholder estimate: about 34.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the KRAS Inhibitors market report cover?
The report splits the market by target (KRAS G12C, KRAS G12D, Pan-KRAS), indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the KRAS Inhibitors market?
Key players include Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines and Novartis AG.
What is driving the KRAS Inhibitors market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.
Who regulates KRAS Inhibitors in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on KRAS Inhibitors are running in France?
58 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
How much research is published on KRAS Inhibitors?
PubMed lists 440 papers on KRAS Inhibitors added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on oncology

See the topic